Brainomix, an organization providing AI-powered imaging instruments for stroke and lung fibrosis, introduced the completion of an $18 million Collection C funding spherical.
The spherical was co-led by current buyers Parkwalk Advisors and the Boehringer Ingelheim Enterprise Fund.
New investor Hostplus through the IP Group Hostplus Innovation Fund and LifeSci Capital participated within the spherical.
WHAT IT DOES
Brainomix is an AI-powered software program platform that allows precision drugs for higher remedy selections in stroke and lung fibrosis. The corporate’s Brainomix 360 e-Lung know-how predicts the development of stroke and lung fibrosis.
The corporate’s Brainomix 360 Stroke automates imaging biomarkers aimed toward enhancing analysis and remedy selections.
The corporate additionally companions with Boehringer Ingelheim to guage the real-world affect of e-Lung and enhance the identification and entry to remedy for folks with progressive lung fibrosis.
Brainomix will use the funds to speed up its industrial growth into the U.S., the place it has secured 10 FDA clearances.
The funding may also help Brainomix’s technique to advance its portfolio of AI-powered know-how in new areas.
“We wish to thank all of the buyers that participated, together with Parkwalk and Boehringer Ingelheim Enterprise Fund for his or her continued help, and welcome Hostplus, all of whom acknowledge the transformative affect that our know-how can have on remedy for stroke and lung fibrosis sufferers,” Michalis Papadakis, CEO and cofounder at Brainomix, stated in an announcement.
“We are going to proceed to harness our place and expertise as a European market chief to attain broad success within the US, serving to enhance affected person care and entry to life-changing therapies.”
MARKET SNAPSHOT
In February, Brainomix partnered with Medtronic Neurovascular. The collaboration aimed to boost stroke look after sufferers throughout Western Europe by integrating AI options into scientific apply, increasing entry to therapies and enhancing affected person outcomes.
In 2023, Brainomix and distant robotic surgical firm Nanoflex Robotics introduced the receipt of £400,000 ($420,418) and CHF 400,000 ($443,700), respectively, to develop an AI-assisted magnetic navigation system for stroke-related robotic surgical instruments.
In 2021, Brainomix closed a sequence B funding spherical with a complete funding of roughly £16 million ($20.7 million). Boehringer Ingelheim Enterprise Fund and Oxford College Innovation Fund led the spherical with participation from Tencent Holdings.
Discussion about this post